More on BLRX
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $3.16 |
|
|||
| Open | $3.21 | ||||
| 52 Wk High | $1.63 | ||||
| 52 Wk Low | $0.71 | ||||
| Day High | $3.37 | ||||
| Day Low | $3.15 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 12,019 | ||||
- BioLineRx (BLRX) Reports In-Line Q1 EPS
- Form 6-K BioLineRx Ltd. For: May 27
- BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update
- BioLineRx and Hemispherian to present GLIX1 data at ASCO 2026
- Form 6-K BioLineRx Ltd. For: May 22
- BioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
- BioLineRx to Report First Quarter 2026 Results on May 27, 2026
- Form 6-K BioLineRx Ltd. For: May 19
- BioLineRx reports positive preclinical data for GLIX1 in brain cancer
- BioLineRx and Hemispherian Announce New GLIX1 Data Demonstrating Potent Anti-Tumor Effect in Glioblastoma (GBM) Across Multiple In-Vivo Studies, Including a Temozolomide (TMZ)-Resistant Model with Pat
Entities mentioned with BLRX
- Twitter | View Related Stories »
- Earnings | View Related Stories »
- FDA | View Related Stories »
- Definitive Agreement | View Related Stories »
- 13G | View Related Stories »
- H.C. Wainwright | View Related Stories »
- PDUFA | View Related Stories »
- Roth Capital | View Related Stories »
- Show More...
